丹参酮ⅡA磺酸钠注射液与舒血宁注射液治疗气虚血瘀型冠心病心绞痛的效果比较
|
摘要
目的比较丹参酮ⅡA磺酸钠注射液与舒血宁注射液治疗气虚血瘀型冠心病心绞痛的效果及对患者血液流变学指标的影响。方法选取2016年10月～2017年12月齐齐哈尔医学院附属第二医院收治的168例冠心病心绞痛患者,经中医辨证论治均为气虚血瘀型,按照随机数字表将其分为A组与B组,各84例患者。其中,A组在常规治疗基础上应用舒血宁治疗,B组则在常规治疗基础上应用丹参酮ⅡA磺酸钠治疗。比较两组治疗效果及血液流变学指标变化情况。结果治疗前两组心绞痛发作次数、持续时间、中医症状积分比较,差异无统计学意义(P> 0.05);治疗2、4周后均较治疗前明显降低,且治疗2周后B组心绞痛发作次数、中医症状积分明显低于A组,心绞痛持续时间短于A组,差异有统计学意义(P <0.05);治疗4周后两组心绞痛发作次数、持续时间、中医症状积分比较,差异无统计学意义(P> 0.05)。治疗4周后两组心绞痛治疗总有效率、心电图总有效率比较,差异无统计学意义(P> 0.05)。两组治疗期间均未发生严重药物不良反应或并发症。结论丹参酮ⅡA磺酸钠注射液与舒血宁注射液用于治疗气虚血瘀型冠心病心绞痛均具有良好的疗效与安全性表现,起效迅速。
Objective To compare the efficacy of Tanshinone ⅡA Sodium Injection and Shuxuening Injection in the treatment of angina pectoris and coronary heart disease of qi-stagnancy and blood stasis. Methods From October 2016 to December 2017, 168 patients with coronary heart disease and angina pectoris were selected. All patients were diagnosed by syndrome differentiation based on traditional Chinese medicine, they were divided into group A and group B by random number table method, 84 patients in each groups. Group A was treated with Shuxuening Injection on the basis of routine treatment, and group B was treated with Tanshinone ⅡA Sodium Injection on the basis of routine treatment. The treatment effects and changes of hemorheology indexes in the two groups were compared. Results Before treatment, the number of episodes of angina pectoris, duration, and symptom scores of traditional Chinese medicine in two groups were compared, the differences were not statistically significant(P > 0.05); after 2, 4 weeks of treatment,these in two groups were significantly lower than before treatment, and after 2 weeks of treatment, the number of episodes of angina pectoris, and symptom scores of traditional Chinese medicine in group B were lower than group A,and the duration of angina pectoris was shorter than the group B, the differences were statistically significant(P <0.05); after 4 weeks of treatment, the number of episodes of angina pectoris, duration, and symptom scores of traditional Chinese medicine in two groups were compared, the differences were not statistically significant(P > 0.05). After 4 weeks of treatment, the total effective rate of angina pectoris treatment, total effective rate of ECG in two groups were compared, the differences were not statistically significant(P > 0.05). No serious adverse drug reactions and complication happened during treatment. Conclusion Both Tanshinone ⅡA Sodium Sulfonate Injection and Shuxuening Injection have good efficacy and safety in the treatment of angina pectoris and coronary heart disease of qi-stagnancy and blood stasis, the effect of Tanshinone ⅡA Sodium Injection is more rapid.
Objective To compare the efficacy of Tanshinone ⅡA Sodium Injection and Shuxuening Injection in the treatment of angina pectoris and coronary heart disease of qi-stagnancy and blood stasis. Methods From October 2016 to December 2017, 168 patients with coronary heart disease and angina pectoris were selected. All patients were diagnosed by syndrome differentiation based on traditional Chinese medicine, they were divided into group A and group B by random number table method, 84 patients in each groups. Group A was treated with Shuxuening Injection on the basis of routine treatment, and group B was treated with Tanshinone ⅡA Sodium Injection on the basis of routine treatment. The treatment effects and changes of hemorheology indexes in the two groups were compared. Results Before treatment, the number of episodes of angina pectoris, duration, and symptom scores of traditional Chinese medicine in two groups were compared, the differences were not statistically significant(P > 0.05); after 2, 4 weeks of treatment,these in two groups were significantly lower than before treatment, and after 2 weeks of treatment, the number of episodes of angina pectoris, and symptom scores of traditional Chinese medicine in group B were lower than group A,and the duration of angina pectoris was shorter than the group B, the differences were statistically significant(P <0.05); after 4 weeks of treatment, the number of episodes of angina pectoris, duration, and symptom scores of traditional Chinese medicine in two groups were compared, the differences were not statistically significant(P > 0.05). After 4 weeks of treatment, the total effective rate of angina pectoris treatment, total effective rate of ECG in two groups were compared, the differences were not statistically significant(P > 0.05). No serious adverse drug reactions and complication happened during treatment. Conclusion Both Tanshinone ⅡA Sodium Sulfonate Injection and Shuxuening Injection have good efficacy and safety in the treatment of angina pectoris and coronary heart disease of qi-stagnancy and blood stasis, the effect of Tanshinone ⅡA Sodium Injection is more rapid.
引文
[1]盛和振.中西医结合治疗冠心病心绞痛的临床疗效观察[J].河南医学研究,2015,24(11):86-87.
[2]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:526.
[3]崔焕俊.阿司匹林肠溶片联合氯吡格雷治疗冠心病心绞痛疗效观察[J].当代医学,2015,3(3):125-126.
[4]蔡兴芬,陈龙胜,吴春美.血府逐瘀汤联合西药治疗冠心病心绞痛的疗效观察及其对血液流变学影响[J].中国中医药科技,2015,22(3):317-318.
[5]樊蓉,任天舒,赵庆春,等.西药常规治疗联用通心络胶囊治疗冠心病心绞痛疗效的荟萃分析[J].药学实践杂志,2015,33(1):83-87.
[6]施惠燕.中西医结合治疗冠心病心绞痛临床疗效分析[J].医学美学美容:旬刊,2015,22(2):220-221.
[7]伦志伟,于庆萍.对比中西医结合治疗和单纯西医治疗冠心病心绞痛的疗效及经济效果[J].中西医结合心血管病杂志:电子版,2015,3(19):40-41.
[8]吴嘉瑞,李怡,谭迪,等.基于Meta分析的舒血宁注射液治疗冠心病心绞痛的临床评价研究[J].中国医院用药评价与分析,2017,17(11):1452-1456.
[9]苏洪义.丹参酮ⅡA磺酸钠注射对急性脑梗死患者血流变学影响分析[J].中国实用医药,2011,6(30):31-32.
[10]肖珩.中医辨证治疗冠心病心绞痛的体会[J].中国民族民间医药,2013,22(7):151-152.
[11]谭迪,吴嘉瑞,崔盈盈,等.基于Meta分析的舒血宁注射液对比丹参类注射液治疗冠心病心绞痛临床评价研究[J].药物流行病学杂志,2018,27(1):20-26.
[12]成磊.冠心病心绞痛应用舒血宁联合曲美他嗪治疗的可行性研究[J].中西医结合心血管病电子杂志,2016,4(14):134-135.
[13]李增才,刘现忠,王兵济.丹参酮ⅡA磺酸钠注射液联合阿霉素对化疗致心肌损伤的疗效观察[J].实用临床医药杂志,2016,20(7):170-171.
[14]李增祥,张琼琼.丹参酮ⅡA磺酸钠联合稳心颗粒对冠心病心绞痛并发室性早搏临床症状的疗效观察[J].白求恩医学杂志,2017,15(1):52-54.
[15]唐梅森,黄政德,向忠军,等.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证68例疗效观察[J].中医杂志,2015,56(5):395-397.
[16]曹甜甜,徐海丽,贺延.丹参酮ⅡA磺酸钠治疗冠心病的疗效及对血液流变学、细胞因子和血脂水平的影响[J].心血管康复医学杂志,2017,26(1):104-107.
[17]陈晶.稳心颗粒与丹参酮ⅡA磺酸钠应用在冠心病心律失常患者治疗中的临床分析研究[J].临床医药文献电子杂志,2017,4(5):957-957.
[18]何红.丹参酮ⅡA磺酸钠辅助治疗冠心病患者的效果及其对血液流变学水平的影响[J].临床医学研究与实践,2018,28(11):115-118.
[19]石晓萍,李静潘雯,吕迁洲,等.我院125例住院患者使用丹参酮ⅡA磺酸钠注射液的安全性分析[J].上海医药,2016,37(19):58-63.
[20]秦宏杰,陈新光.丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病的临床效果[J].中国医药导报,2017,14(26):130-133.
[2]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:526.
[3]崔焕俊.阿司匹林肠溶片联合氯吡格雷治疗冠心病心绞痛疗效观察[J].当代医学,2015,3(3):125-126.
[4]蔡兴芬,陈龙胜,吴春美.血府逐瘀汤联合西药治疗冠心病心绞痛的疗效观察及其对血液流变学影响[J].中国中医药科技,2015,22(3):317-318.
[5]樊蓉,任天舒,赵庆春,等.西药常规治疗联用通心络胶囊治疗冠心病心绞痛疗效的荟萃分析[J].药学实践杂志,2015,33(1):83-87.
[6]施惠燕.中西医结合治疗冠心病心绞痛临床疗效分析[J].医学美学美容:旬刊,2015,22(2):220-221.
[7]伦志伟,于庆萍.对比中西医结合治疗和单纯西医治疗冠心病心绞痛的疗效及经济效果[J].中西医结合心血管病杂志:电子版,2015,3(19):40-41.
[8]吴嘉瑞,李怡,谭迪,等.基于Meta分析的舒血宁注射液治疗冠心病心绞痛的临床评价研究[J].中国医院用药评价与分析,2017,17(11):1452-1456.
[9]苏洪义.丹参酮ⅡA磺酸钠注射对急性脑梗死患者血流变学影响分析[J].中国实用医药,2011,6(30):31-32.
[10]肖珩.中医辨证治疗冠心病心绞痛的体会[J].中国民族民间医药,2013,22(7):151-152.
[11]谭迪,吴嘉瑞,崔盈盈,等.基于Meta分析的舒血宁注射液对比丹参类注射液治疗冠心病心绞痛临床评价研究[J].药物流行病学杂志,2018,27(1):20-26.
[12]成磊.冠心病心绞痛应用舒血宁联合曲美他嗪治疗的可行性研究[J].中西医结合心血管病电子杂志,2016,4(14):134-135.
[13]李增才,刘现忠,王兵济.丹参酮ⅡA磺酸钠注射液联合阿霉素对化疗致心肌损伤的疗效观察[J].实用临床医药杂志,2016,20(7):170-171.
[14]李增祥,张琼琼.丹参酮ⅡA磺酸钠联合稳心颗粒对冠心病心绞痛并发室性早搏临床症状的疗效观察[J].白求恩医学杂志,2017,15(1):52-54.
[15]唐梅森,黄政德,向忠军,等.加味丹参饮联合西药治疗冠心病心绞痛心血瘀阻证68例疗效观察[J].中医杂志,2015,56(5):395-397.
[16]曹甜甜,徐海丽,贺延.丹参酮ⅡA磺酸钠治疗冠心病的疗效及对血液流变学、细胞因子和血脂水平的影响[J].心血管康复医学杂志,2017,26(1):104-107.
[17]陈晶.稳心颗粒与丹参酮ⅡA磺酸钠应用在冠心病心律失常患者治疗中的临床分析研究[J].临床医药文献电子杂志,2017,4(5):957-957.
[18]何红.丹参酮ⅡA磺酸钠辅助治疗冠心病患者的效果及其对血液流变学水平的影响[J].临床医学研究与实践,2018,28(11):115-118.
[19]石晓萍,李静潘雯,吕迁洲,等.我院125例住院患者使用丹参酮ⅡA磺酸钠注射液的安全性分析[J].上海医药,2016,37(19):58-63.
[20]秦宏杰,陈新光.丹参酮ⅡA磺酸钠注射液治疗老年肺源性心脏病的临床效果[J].中国医药导报,2017,14(26):130-133.